Evidence digest · GLP-1 receptor agonist
Semaglutide is a GLP-1 receptor agonist that acts on the brain to lower appetite.
A measured reading of what the trials actually measured — the central appetite circuitry, the STEP, SUSTAIN, SELECT and FLOW readouts, and where the evidence is settled versus still open.
The short version
Semaglutide is a prescription medicine in a class called GLP-1 receptor agonists — drugs that copy a natural gut hormone your body makes after you eat. That hormone, GLP-1 (glucagon-like peptide-1), tells the pancreas to release insulin, slows how fast the stomach empties, and quiets hunger. Semaglutide is a longer-lasting copy of it, engineered to stay in the body for about a week.
Most of its weight effect happens in the brain. The drug reaches the appetite-control regions and turns down the constant pull toward food, so people eat less and feel full sooner. In studies of type 2 diabetes it lowered blood sugar; in obesity it produced large, sustained weight loss; and in people with heart disease it lowered the rate of heart attacks and strokes. It also has real downsides — mostly stomach-related — and some cautions worth knowing. What people report, including the downsides, is on the effects page. This site is a reading digest of the published science, not medical advice.
What is semaglutide
Semaglutide is a 31-amino-acid peptide — a short protein-like chain — built as a close analogue of human GLP-1, the gut hormone that signals fullness after a meal [4]. Two small edits to the chain make it durable: a swap at position 8 blocks the enzyme (DPP-4) that normally chews up natural GLP-1 within minutes, and a fatty-acid tail lets the molecule cling to albumin, the most abundant protein in blood. Bound to albumin, semaglutide is shielded from rapid clearance, which is why one injection lasts a week rather than two minutes [5].
That engineering is the whole point. Native GLP-1 is a powerful appetite and glucose signal, but it vanishes too fast to be a drug. Semaglutide keeps the same signal switched on long enough to matter. It is approved as both a once-weekly injection and a once-daily tablet, and it carries the generic name semaglutide — the name used throughout this digest in place of any brand.
Why the appetite story leads
The clearest way to understand semaglutide is to start in the brain, because that is where most of its weight effect comes from. In rodents, semaglutide reached the brainstem and the hypothalamus — the appetite headquarters — by entering through regions with a leaky blood-brain barrier, then reduced food intake and shifted food preference without lowering how many calories the body burned at rest [4]. The drug did not make the animals burn more; it made them want less.
Inside the hypothalamus sits the arcuate nucleus, a cluster with two opposing crews of neurons: POMC/CART cells that say stop eating and NPY/AgRP cells that say keep eating. GLP-1 receptor agonists turn up the satiety crew and turn down the hunger crew, and the effect depends on the body's metabolic state and timing [8]. Foundational work in mice showed the arcuate nucleus is required for this class of drug to produce weight loss in the first place [9]. The semaglutide mechanism of action page walks through that circuitry in detail.
What the trials showed
The headline weight figure comes from STEP 1: in adults with overweight or obesity and no diabetes, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% over 68 weeks, against -2.4% on placebo — roughly a 12-percentage-point difference [1]. In type 2 diabetes at high cardiovascular risk, SUSTAIN-6 found semaglutide cut the rate of cardiovascular death, heart attack or stroke (hazard ratio 0.74) [2]. In people with established heart disease and obesity but no diabetes, the much larger SELECT trial (17,604 participants) confirmed a 20% reduction in those same events [3].
The benefits extended to the kidneys: in FLOW, semaglutide lowered the risk of major kidney-disease events by 24% in type 2 diabetes with chronic kidney disease [6]. Across this record the pattern is consistent and the trials are large. The honest caveats — the side effects, the open safety questions, and what happens when people stop — are laid out plainly across the Semaglutide research and Semaglutide effects pages.
Semaglutide peptide: an approved medicine, not a research-only compound
It is worth being precise about what semaglutide is, because the word peptide gets used loosely online. Semaglutide is a peptide by chemistry — a manufactured chain of amino acids — but it is also an FDA-approved prescription medicine across several indications: type 2 diabetes, chronic weight management, lowering cardiovascular events in established heart disease, and, as of 2025, a form of fatty liver disease called MASH [1][3][6]. That separates it from the research-only peptides that have never cleared human trials.
This digest summarizes the published clinical record and approved-label information. It does not sell anything, does not name brands, and does not recommend a dose for any individual. Where doses appear, they are the doses studied in the cited trials or stated on the label, reported in the third person.